
## Eoin P Brennan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9531013/publications.pdf Version: 2024-02-01



FOIN P RDENNAN

#	Article	IF	CITATIONS
1	Genetic studies of body mass index yield new insights for obesity biology. Nature, 2015, 518, 197-206.	13.7	3,823
2	New genetic loci link adipose and insulin biology to body fat distribution. Nature, 2015, 518, 187-196.	13.7	1,328
3	Mesenchymal Stem Cells Deliver Exogenous MicroRNA-let7c via Exosomes to Attenuate Renal Fibrosis. Molecular Therapy, 2016, 24, 1290-1301.	3.7	286
4	New Susceptibility Loci Associated with Kidney Disease in Type 1 Diabetes. PLoS Genetics, 2012, 8, e1002921.	1.5	216
5	Lipoxins Attenuate Renal Fibrosis by Inducing let-7c and Suppressing TGFβR1. Journal of the American Society of Nephrology: JASN, 2013, 24, 627-637.	3.0	140
6	Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen. Journal of the American Society of Nephrology: JASN, 2019, 30, 2000-2016.	3.0	135
7	Protective Effect of let-7 miRNA Family in Regulating Inflammation in Diabetes-Associated Atherosclerosis. Diabetes, 2017, 66, 2266-2277.	0.3	130
8	The Atlas of Inflammation Resolution (AIR). Molecular Aspects of Medicine, 2020, 74, 100894.	2.7	110
9	Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function. Nature Reviews Nephrology, 2021, 17, 725-739.	4.1	85
10	Next-generation sequencing identifies TGF-β1-associated gene expression profiles in renal epithelial cells reiterated in human diabetic nephropathy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 589-599.	1.8	80
11	Association Testing of Previously Reported Variants in a Large Case-Control Meta-analysis of Diabetic Nephropathy. Diabetes, 2012, 61, 2187-2194.	0.3	77
12	Chromosome 2q31.1 Associates with ESRD in Women with Type 1 Diabetes. Journal of the American Society of Nephrology: JASN, 2013, 24, 1537-1543.	3.0	66
13	Genetic Evidence for a Causal Role of Obesity in Diabetic Kidney Disease. Diabetes, 2015, 64, 4238-4246.	0.3	63
14	Lipoxins Protect Against Inflammation in Diabetes-Associated Atherosclerosis. Diabetes, 2018, 67, 2657-2667.	0.3	60
15	Lipoxins Regulate the Early Growth Response–1 Network and Reverse Diabetic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2018, 29, 1437-1448.	3.0	48
16	Therapeutic Potential of Lipoxin A <sub>4</sub> in Chronic Inflammation: Focus on Cardiometabolic Disease. ACS Pharmacology and Translational Science, 2020, 3, 43-55.	2.5	40
17	Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A4 mimetics (sLXms). European Journal of Medicinal Chemistry, 2019, 162, 80-108.	2.6	38
18	The Genetics of Diabetic Nephropathy. Genes, 2013, 4, 596-619.	1.0	36

EOIN P BRENNAN

#	Article	IF	CITATIONS
19	Comparative analysis of DNA methylation profiles in peripheral blood leukocytes versus lymphoblastoid cell lines. Epigenetics, 2009, 4, 159-164.	1.3	34
20	Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential. European Journal of Medicinal Chemistry, 2021, 213, 113167.	2.6	34
21	NR4A Receptors Differentially Regulate NF-κB Signaling in Myeloid Cells. Frontiers in Immunology, 2017, 8, 7.	2.2	33
22	Extracellular vesicles from monocyte/platelet aggregates modulate human atherosclerotic plaque reactivity. Journal of Extracellular Vesicles, 2021, 10, 12084.	5.5	32
23	Assessment of differentially methylated loci in individuals with end-stage kidney disease attributed to diabetic kidney disease: an exploratory study. Clinical Epigenetics, 2021, 13, 99.	1.8	29
24	DNA methylation profiling in cell models of diabetic nephropathy. Epigenetics, 2010, 5, 396-401.	1.3	28
25	Specialized Pro-resolving Lipid Mediators: Modulation of Diabetes-Associated Cardio-, Reno-, and Retino-Vascular Complications. Frontiers in Pharmacology, 2018, 9, 1488.	1.6	28
26	Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E–Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 447-458.	1.3	27
27	microRNA-155 Is Decreased During Atherosclerosis Regression and Is Increased in Urinary Extracellular Vesicles During Atherosclerosis Progression. Frontiers in Immunology, 2020, 11, 576516.	2.2	26
28	RAGE Deletion Confers Renoprotection by Reducing Responsiveness to Transforming Growth Factor-Î <sup>2</sup> and Increasing Resistance to Apoptosis. Diabetes, 2018, 67, 960-973.	0.3	23
29	Therapeutic potential of pro-resolving mediators in diabetic kidney disease. Advanced Drug Delivery Reviews, 2021, 178, 113965.	6.6	23
30	Specialized pro-resolving mediators in renal fibrosis. Molecular Aspects of Medicine, 2017, 58, 102-113.	2.7	22
31	Therapeutic potential of the FPR2/ALX agonist AT-01-KG in the resolution of articular inflammation. Pharmacological Research, 2021, 165, 105445.	3.1	19
32	Asymmetric Synthesis and Biological Screening of Quinoxaline-Containing Synthetic Lipoxin A <sub>4</sub> Mimetics (QNX-sLXms). Journal of Medicinal Chemistry, 2021, 64, 9193-9216.	2.9	18
33	Paricalcitol protects against TGF-β1-induced fibrotic responses in hypoxia and stabilises HIF-α in renal epithelia. Experimental Cell Research, 2015, 330, 371-381.	1.2	16
34	Genome-wide meta-analysis and omics integration identifies novel genes associated with diabetic kidney disease. Diabetologia, 2022, 65, 1495-1509.	2.9	16
35	Study of micro <scp>RNA</scp> in diabetic nephropathy: Isolation, quantification and biological function. Nephrology, 2015, 20, 132-139.	0.7	15
36	Profibrotic IHG-1 complexes with renal disease associated HSPA5 and TRAP1 in mitochondria. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 896-906.	1.8	13

EOIN P BRENNAN

#	Article	IF	CITATIONS
37	Specialized pro-resolving mediators in diabetes: novel therapeutic strategies. Clinical Science, 2019, 133, 2121-2141.	1.8	12
38	Dysregulation of the interleukin-17A pathway in endometrial tissue from women with unexplained infertility affects pregnancy outcome following assisted reproductive treatment. Human Reproduction, 2020, 35, 1875-1888.	0.4	11
39	Decoding microRNA drivers in atherosclerosis. Bioscience Reports, 2022, 42, .	1.1	11
40	Characterization of the renal cortical transcriptome following Roux-en-Y gastric bypass surgery in experimental diabetic kidney disease. BMJ Open Diabetes Research and Care, 2020, 8, e001113.	1.2	10
41	Targeting cellular drivers and counterâ€regulators of hyperglycaemia―and transforming growth factorâ€ <i>β</i> 1â€associated profibrotic responses in diabetic kidney disease. Experimental Physiology, 2014, 99, 1154-1162.	0.9	9
42	Diagnostic utility of genetic testing in patients undergoing renal biopsy. Journal of Physical Education and Sports Management, 2020, 6, a005462.	0.5	7
43	miRNAs in the Pathophysiology of Diabetes and Their Value as Biomarkers. , 2016, , 643-661.		4
44	The Molecular Effects of a High Fat Diet on Endometrial Tumour Biology. Life, 2020, 10, 188.	1.1	4
45	Medications Activating Tubular Fatty Acid Oxidation Enhance the Protective Effects of Roux-en-Y Gastric Bypass Surgery in a Rat Model of Early Diabetic Kidney Disease. Frontiers in Endocrinology, 2021, 12, 757228.	1.5	4
46	Promoting resolution in kidney disease. Current Opinion in Nephrology and Hypertension, 2020, 29, 119-127.	1.0	2